Last reviewed · How we verify
AGN-195263 0.1%
AGN-195263 is a topical ophthalmic agent that modulates intraocular pressure through enhanced aqueous humor outflow.
AGN-195263 is a topical ophthalmic agent that modulates intraocular pressure through enhanced aqueous humor outflow. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | AGN-195263 0.1% |
|---|---|
| Sponsor | Allergan |
| Drug class | Prostaglandin F receptor agonist |
| Target | FP receptor (prostaglandin F receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
AGN-195263 is a selective prostaglandin F (FP) receptor agonist formulated as a 0.1% ophthalmic solution. It increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. This mechanism is typical of prostaglandin analogs used in glaucoma and ocular hypertension management.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation changes
- Eyelash growth
- Eye irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-195263 0.1% CI brief — competitive landscape report
- AGN-195263 0.1% updates RSS · CI watch RSS
- Allergan portfolio CI